Study on the Impact of Electroacupuncture Combined With Self-Acupressure on the Quality of Life of Patients With Early-Stage Breast Cancer Undergoing Chemotherapy

NCT06601621 · tracked via the Priya Life Science China tracker

Sponsor

Jiuda Zhao

Phase

Not applicable

Started

2024-10-19

Last updated

2026-02-12

Condition(s) studied

ElectroacupunctureQuality of Life (QOL)AcupressureBreast CancerChemotherapy

Investigational drug(s) / intervention(s)

electroacupuncture+ self-acupressuresham electroacupuncture + sham self-acupressure

electroacupuncture+ self-acupressure: Participants will receive two electroacupuncture treatments within the first week of each treatment cycle. The acupuncturist inserts the needle into the point and manipulates the needle until the feeling of "deqi"; is achieved and reported by the participant. The electrical stimulation will be administered at a sustained frequency of 2/10Hz for 30 minutes. self-acupressure: In weeks 2 and 3 of each treatment cycle, participants performed true self-administered acupressure, pressing each acupoint with their thumb to achieve "deqi"; for three minutes.

sham electroacupuncture + sham self-acupressure: Sham electroacupuncture: The sham electroacupuncture shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive acupuncture treatment without electrical stimulation same the intervention group. And avoid "deqi"; sensation. Sham self-acupressure: Administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of "deqi".

Study summary

This randomized controlled clinical trial aims to evaluate the effect of electroacupuncture combined with self-acupressure on the quality of life of early-stage breast cancer patients receiving chemotherapy.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: 1. Aged 18 years or older and aged 75 years or younger, inclusive. with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; 2. Patients who have not received prior chemotherapy and are scheduled to receive at least 4 cycles of adjuvant or neoadjuvant chemotherapy or combination targeted therapy; 3. Normal organ function with platelets ≥ 100\*10\^9/ L, hemoglobin ≥ 90 g/L, serum creatinine ≤ 1.5 mg/dl (133 mmol/L), or creatinine clearance ≥ 60 ml/min, total bilirubin ≤ 1.5 times the upper limit of normal (ULN), alanine aminotransferase ≤ 2.5 times ULN, and aspartate aminotransferase ≤ 2.5 times ULN; 4. Premenopausal women need appropriate contraception; 5. Ability to understand the study well and complete the study questionnaire. Exclusion Criteria: 1. Patients with needle phobia or allergy to stainless steel needles; and 2. Current diagnosis of mental illness (e.g., major depression, obsessive-compulsive disorder, or schizophrenia); 3. History of autoimmune diseases, blood disorders, or organ transplantation, or long-term use of hormones or immunosuppressants; 4. Comorbid bleeding disorders or thyroid dysfunction; 5. Implantation of a pacemaker; pregnancy or breastfeeding; 6. A plan for adjuvant radiotherapy in the upcoming chemotherapy cycle; 7. Current active infection; 8. Acupuncture treatment within the last four weeks; 9. Patients who are allergic to the drugs used; 10. Use of other Traditional Chinese Medicine (TCM) techniques such as Chinese herbs in the next chemotherapy cycle.

Primary outcome measure(s)

Differences in quality of life during the overall stage — Chemotherapy treatment was initiated to 21 days after the last chemotherapy cycle
Difference in change in EQ-5D-5L scores from first to last assessment between two arms

Trial sites (1)

Facility	City	Region	Status
Qinghai University Affiliated Hospital	Xining	Qinghai	Recruiting

More Jiuda Zhao trials in China

Combined Intrathecal and Systemic Therapy With Trastuzumab Rezetecan for Leptomeningeal Metastases Starting soon

Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer Recruiting

Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer Recruiting

Other trials for the same condition

Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer Recruiting

Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy Recruiting

A Stuty on the Treatment and Nursing Care of CIPN Patients With Traditional Chinese Medicine Hot Package Recruiting

A Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological Maps Recruiting

Research on the Development and Validation of Personalized Exercise Prescription System for Breast Cancer Patients Based on Large Language Models Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06601621 on ClinicalTrials.gov ↗ ← All trials in China